Mass Spectrometry-Based Proteomic Discovery of Prognostic Biomarkers in Adrenal Cortical Carcinoma

被引:22
|
作者
Jang, Han Na [1 ,2 ]
Moon, Sun Joon [1 ,3 ]
Jung, Kyeong Cheon [4 ,5 ,6 ]
Kim, Sang Wan [1 ,7 ]
Kim, Hyeyoon [8 ]
Han, Dohyun [8 ]
Kim, Jung Hee [1 ,2 ]
机构
[1] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul 03080, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 03080, South Korea
[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Div Endocrinol & Metab,Sch Med, Seoul 03080, South Korea
[4] Seoul Natl Univ, Dept Pathol, Coll Med, Seoul 03080, South Korea
[5] Seoul Natl Univ, Dept Translat Med, Coll Med, Seoul 03080, South Korea
[6] Seoul Natl Univ, Grad Sch, Integrated Major Innovat Med Sci, Seoul 03080, South Korea
[7] Seoul Natl Univ, Dept Internal Med, Seoul Metropolitan Govt, Boramae Med Ctr, Seoul 03080, South Korea
[8] Seoul Natl Univ Hosp, Biomed Res Inst, Prote Core Facil, Seoul 03080, South Korea
基金
新加坡国家研究基金会;
关键词
adrenal cortical carcinoma; prognosis; proteomics; mass spectrometry; HNRNPA1; ADRENOCORTICAL CARCINOMA; GENOMIC CHARACTERIZATION; COMPUTATIONAL PLATFORM; POOR-PROGNOSIS; EXPRESSION; PROTEIN; TUMORS; CLASSIFICATION; DISEASE; PREDICTORS;
D O I
10.3390/cancers13153890
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Adrenal cortical carcinoma (ACC) is an extremely rare disease with a variable prognosis. Current prognostic markers have limitations in identifying patients with a poor prognosis and who require adjuvant therapy. We developed the prognostic biomarker candidates of ACC using mass-spectrometry-based proteomics and machine learning algorithm. We further validated them in The Cancer Genome Atlas data and performed the survival analysis according to the expression levels of each protein. In addition, HNRNPA1, the protein identified as a prognostic marker of ACC based on proteomics, was validated in the immunohistochemistry staining. The prognostic protein biomarkers of ACC found in this study are expected to help determine the appropriate treatment plan for patients. Adrenal cortical carcinoma (ACC) is an extremely rare disease with a variable prognosis. Current prognostic markers have limitations in identifying patients with a poor prognosis. Herein, we aimed to investigate the prognostic protein biomarkers of ACC using mass-spectrometry-based proteomics. We performed the liquid chromatography-tandem mass spectrometry (LC-MS/MS) using formalin-fixed paraffin-embedded (FFPE) tissues of 45 adrenal tumors. Then, we selected 117 differentially expressed proteins (DEPs) among tumors with different stages using the machine learning algorithm. Next, we conducted a survival analysis to assess whether the levels of DEPs were related to survival. Among 117 DEPs, HNRNPA1, C8A, CHMP6, LTBP4, SPR, NCEH1, MRPS23, POLDIP2, and WBSCR16 were significantly correlated with the survival of ACC. In age- and stage-adjusted Cox proportional hazard regression models, only HNRNPA1, LTBP4, MRPS23, POLDIP2, and WBSCR16 expression remained significant. These five proteins were also validated in TCGA data as the prognostic biomarkers. In this study, we found that HNRNPA1, LTBP4, MRPS23, POLDIP2, and WBSCR16 were protein biomarkers for predicting the prognosis of ACC.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] Mass Spectrometry-Based Metabolomic and Proteomic Strategies in Organic Acidemias
    Imperlini, Esther
    Santorelli, Lucia
    Orru, Stefania
    Scolamiero, Emanuela
    Ruoppolo, Margherita
    Caterino, Marianna
    BIOMED RESEARCH INTERNATIONAL, 2016, 2016
  • [32] ANYL 318-Discovery and validation of astrocytoma biomarkers using microdissected tissue specimens coupled with targeted and mass spectrometry-based proteomic studies
    Guo, Tong
    Wang, Weijie
    Lee, Cheng S.
    Zhuang, Zhengping
    Weil, Robert
    Balgley, Brian M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234
  • [33] Statistical Design of Quantitative Mass Spectrometry-Based Proteomic Experiments
    Oberg, Ann L.
    Vitek, Olga
    JOURNAL OF PROTEOME RESEARCH, 2009, 8 (05) : 2144 - 2156
  • [34] Progress in mass spectrometry-based proteomic research of tumor hypoxia
    Gao, Zhiqi
    Luo, Gang
    Ni, Bing
    ONCOLOGY REPORTS, 2017, 38 (02) : 676 - 684
  • [35] Mass spectrometry-based proteomic applications in dental implants research
    Halstenbach, Tim
    Topitsch, Annika
    Schilling, Oliver
    Iglhaut, Gerhard
    Nelson, Katja
    Fretwurst, Tobias
    PROTEOMICS CLINICAL APPLICATIONS, 2024, 18 (03)
  • [36] Mass spectrometry-based proteomic analysis of the DNA damage response
    Stokes, Matthew P.
    Zhu, Yiying
    Farnsworth, Charles L.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2018, 23 : 597 - 613
  • [37] Mass spectrometry-based proteomic analyses of contact lens deposition
    Green-Church, Kari B.
    Nichols, Jason J.
    MOLECULAR VISION, 2008, 14 (36-37): : 291 - 297
  • [38] Mass Spectrometry-Based Proteomic Profiling of a Silvaner White Wine
    Albuquerque, Wendell
    Ghezellou, Parviz
    Seidel, Leif
    Burkert, Johannes
    Will, Frank
    Schweiggert, Ralf
    Spengler, Bernhard
    Zorn, Holger
    Gand, Martin
    BIOMOLECULES, 2023, 13 (04)
  • [39] Biomarkers of Adrenal Cortical Carcinoma
    Mete, O.
    Gucer, H.
    Kefeli, M.
    Asa, S. L.
    MODERN PATHOLOGY, 2014, 27 : 156A - 156A
  • [40] Biomarkers of Adrenal Cortical Carcinoma
    Mete, O.
    Gucer, H.
    Kefeli, M.
    Asa, S. L.
    LABORATORY INVESTIGATION, 2014, 94 : 156A - 156A